FLT3 Mutations: Significance in Paediatric AML

Patients with acute myeloid leukaemia (AML) who have FMS-like tyrosine kinase 3 (FLT3) mutations are a concern for haematologists. Many studies indicate that these patients have poor prognosis. Due to the dearth of research in this area, the role of allogeneic transplantation as a therapy is still controversial. But the available limited data suggest that transplantation in first remission is possibly the first choice. As FTL3 mutations in AML result in poor patient outcomes, different FLT3 inhibitors are used as specific targeted therapy.